Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

V-007

Supelco

O-Desmethylvenlafaxine solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C16H25NO2
Numero CAS:
93413-62-8
Peso molecolare:
263.38
Numero CE:
200-659-6
Numero MDL:
MFCD00871934
Codice UNSPSC:
41116107
ID PubChem:
329828919
NACRES:
NA.24

Grado

certified reference material

Stato

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

Concentrazione

100 μg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

clinical testing

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

OC1=CC=C(C(CN(C)C)C2(O)CCCCC2)C=C1

InChI

1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
KYYIDSXMWOZKMP-UHFFFAOYSA-N

Informazioni sul gene

human ... SLC6A2(6530) , SLC6A4(6532)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

An analytical reference standard applicable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications such as urine drug testing, forensic analysis, or clinical toxicology. Also known as desvenlafaxine, O-desmethylvenlafaxine is an SNRI antidepressant marketed under the trade name Pristiq® for the treatment of depression. O-desmethylvenlafaxine is also a major urinary metabolite of venlafaxine, an SNRI antidepressant sold as Effexor® or Efexor and used to treat major depressive disorder, generalized anxiety disorder, and other anxiety disorders associated with depression.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Effexor is a registered trademark of American Home Product Corp.
Pristiq is a registered trademark of Wyeth LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Elenchi normativi

Forniamo informazioni su eventuali restrizioni prevalentemente per i prodotti chimici. Per altre tipologie di prodotto siamo in grado di fornire soltanto informazioni limitate. Nessuna segnalazione significa che nessuno dei componenti è citato in un elenco. È dovere dell’utilizzatore assicurarsi che il prodotto venga impiegato in maniera sicura e a norme di legge.

EU REACH Annex XVII (Restriction List)

CAS No.

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Anita H Clayton et al.
The journal of sexual medicine, 10(3), 768-776 (2012-08-22)
The symptoms of major depressive disorder (MDD) include sexual dysfunction, but antidepressant pharmacotherapies are also associated with treatment-emergent sexual dysfunction. These secondary and post hoc analyses evaluated sexual functioning in employed adult outpatients with MDD treated with desvenlafaxine (administered as
JoAnn V Pinkerton et al.
Menopause (New York, N.Y.), 20(1), 38-46 (2012-12-26)
The purpose of this study was to assess the 1-year maintenance of the efficacy of desvenlafaxine 100 mg/day (administered as desvenlafaxine succinate) established on week 12 in a 1-year, double-blind, randomized, placebo-controlled trial in postmenopausal women seeking treatment of bothersome
G Gasser et al.
Chemosphere, 88(1), 98-105 (2012-03-27)
The stereoselectivity of R,S-venlafaxine and its metabolites R,S-O-desmethylvenlafaxine, N-desmethylvenlafaxine, O,N-didesmethylvenlafaxine, N,N-didesmethylvenlafaxine and tridesmethylvenlafaxine was studied in three processes: (i) anaerobic and aerobic laboratory scale tests; (ii) six wastewater treatment plants (WWTPs) operating under different conditions; and (iii) a variety of
R J Cheng et al.
Climacteric : the journal of the International Menopause Society, 16(1), 17-27 (2012-06-01)
To assess effects of desvenlafaxine (administered as desvenlafaxine succinate) on secondary outcomes of mood, climacteric symptoms, and treatment satisfaction in postmenopausal women with moderate to severe menopausal vasomotor symptoms (VMS). A 12-week, multicenter, double-blind, placebo-controlled trial was conducted in postmenopausal
Nakao Iwata et al.
Journal of psychiatric practice, 19(1), 5-14 (2013-01-22)
This study evaluated the efficacy and safety of low-dose desvenlafaxine (administered as desvenlafaxine succinate) in treating major depressive disorder (MDD). Adult outpatients (aged 18 years) in the United States and (aged 20 years) in Japan, who met Diagnostic and Statistical
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.